Longevity and anti-senescence therapy — medical and scientific approaches designed to extend human lifespan and promote healthy aging by targeting the biological processes that cause aging, cellular damage, and decline in bodily functions — are having more than a moment right now. The industry is on an upward swing, ready to expand from nearly $800 billion to an expected $1,868.2 billion by 2034. That’s a projected compound annual growth rate of approximately 8.2%, driven by products, services, and technologies designed to reverse senescence, the process where cells lose the ability to divide and function properly, and mitigate aging and age-related diseases.
The benefits of the longevity industry are twofold: it provides opportunities to investors and health care practitioners while enhancing and expanding health and quality of life for patients. Let’s take a look at what the market has to say.